Dermatographic Urticaria — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dermatographic urticaria. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
3
Active US patents
60/100
Avg vulnerability
—
Annual revenue covered

Originators in Dermatographic Urticaria

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bayer 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dermatographic urticaria. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
27
2
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tussionex Pennkinetic
CHLORPHENIRAMINE MALEATE
 Bayer 3 60 — 2027-02-28

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9066942 Tussionex Pennkinetic method of use 68 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9107921 Tussionex Pennkinetic formulation 48 2032-01-03

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9107921 Tussionex Pennkinetic formulation 48 2032-01-03
7863287 Tussionex Pennkinetic formulation 65 2027-02-28
9066942 Tussionex Pennkinetic method of use 68 2032-01-03

Related